FDA Hold Review Continues As Newron Advances Phase 3 Evenamide Program

The FDA provided written feedback to Newron Pharmaceuticals on the clinical hold affecting U.S. sites in its Phase 3 ENIGMA-TRS 2 study of evenamide. Newron said it is preparing a response; the article gives no timeline or indication that the hold has been lifted.